从成人到青少年:中轴型脊柱关节炎临床试验与结局的对齐
本文综述了成人中轴型脊柱关节炎(axSpA)与青少年起病中轴型脊柱关节炎(axJSpA)在临床表现、遗传易感性、分类标准和治疗范式上的高度相似性,并指出尽管axJSpA疾病负担显著,但获批治疗选择有限。基于共享的生物学、临床表型、治疗反应模式和结局测量工具,从成人axSpA向儿童axJSpA外推疗效和目标药物暴露数据在科学上是合理的,且对满足未满足的治疗需求至关重要。
要点
- 成人axSpA与axJSpA在症状、遗传易感性和治疗上高度重叠。
- 分类标准对齐:成人用ASAS标准,儿童用新验证的axJSpA标准。
- NSAIDs和TNF抑制剂是成人和儿童的标准治疗,IL-17A/F和JAK抑制跨年龄相关。
核心结论
- 基于共享的生物学、临床表型、治疗反应模式和共同结局测量,从成人axSpA向儿童axJSpA外推疗效和目标药物暴露数据在科学上是合理的。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 高达20%的脊柱关节炎患者症状在16岁前出现。
- 成人axSpA与axJSpA共享重叠的临床症状、遗传易感性和治疗方法。
- 成人axSpA按ASAS标准分类,儿童按新验证的axJSpA标准分类,后者 closely mirrors 成人框架。
- NSAIDs和TNF抑制剂是成人和儿童的标准治疗,IL-17A/F抑制和JAK抑制等新兴机制跨年龄组相关。
- axJSpA缺乏获批药物。
关键数值与推荐
- 成人axSpA分类依据ASAS标准,儿童axJSpA分类依据新验证的axJSpA标准。
- 共同结局测量包括SPARCC MRI炎症和结构评分。
临床怎么用
- 在axJSpA缺乏获批药物的情况下,可考虑基于成人axSpA数据外推疗效和目标药物暴露。
- 临床可借鉴成人axSpA的治疗范式(NSAIDs、TNF抑制剂)管理axJSpA。
局限性
- 综述未报告系统检索范围。
- 未报告具体外推方法的验证数据或定量阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile-onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited. This gap underscores the need for evidence-based approaches to extend effective therapies to children. This review highlights the strong parallels between adult axial SpA (axSpA) and axJSpA, supporting the appropriateness of extrapolating efficacy and target drug exposure data from adults to children. Adult- and axJSpA share key clinical and pathogenic features, including overlapping clinical symptoms, genetic susceptibility, and treatment approaches. Classification systems also align: adult axSpA is classified according to the Assessment of Spondyloarthritis International Society criteria, whereas children are classified using the recently validated axJSpA criteria, which closely mirrors the adult framework. Treatment paradigms further reinforce these similarities. Nonsteroidal anti-inflammatory drugs and tumor necrosis factor inhibitors are standard therapy in both adults and children, and emerging mechanisms, such as inhibition of interleukin-17A/F and JAK, are relevant across age groups. However, the absence of approved agents for axJSpA underscores the importance of leveraging data from adults. Given the shared biology, clinical phenotype, treatment response patterns, and the availability of shared outcome measures such as the Spondyloarthritis Research Consortium of Canada magnetic resonance imaging inflammation and structural scores, extrapolating efficacy and target drug exposure data from adults with axSpA to children with axJSpA is scientifically justified and critical for addressing the unmet therapeutic needs in affected youth.
引用
- Weiss PF, Smith JA, Colbert RA, et al. From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2026. PMID: 42405427. doi:10.1002/acr.80111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。